Posted by Michael Wonder on 18 Jul 2018
FDA grants breakthrough therapy designation for Genentech’s Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma
17 July 2018 - Genentech today announced that the U.S. FDA has granted breakthrough therapy designation for Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) as an initial (first-line) treatment for people with advanced or metastatic hepatocellular carcinoma, the most common form of liver cancer.
The designation is based on data from a Phase Ib study assessing the safety and clinical activity of the combination of Tecentriq and Avastin.
This is the 22nd breakthrough therapy designation for Genentech’s portfolio of medicines and the third for Tecentriq.
